Balyasny Asset Management
PRVB

Balyasny Asset Management’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Balyasny Asset Management’s Portfolio PRVB Stock Details PRVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-588,758
Closed -$14.2M – 3186
2023
Q1 		$14.2M Buy
+588,758
New +$7.39M 0.04% 640

Other funds holding PRVB

UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Balyasny Asset Management's PRVB Position: Q2 2023 in Review

Balyasny Asset Management sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 588,758 shares — an estimated $14.2M sold.

Balyasny Asset Management first reported a position in PRVB in Q1 2023 and held it in 1 quarter. The position peaked at $14.2M in Q1 2023. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.

  • Balyasny Asset Management reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Balyasny Asset Management sold 588,758 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $14.2M.
  • Balyasny Asset Management first reported a position in Provention Bio, Inc. Common Stock in Q1 2023 and held it in 1 quarter.
  • Balyasny Asset Management's Provention Bio, Inc. Common Stock position peaked at $14.2M in Q1 2023.
  • 1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.

Based on Balyasny Asset Management's 13F filing for Q2 2023, filed 14 Aug 2023.